Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001379702 | SCV001577550 | likely pathogenic | Anemia, nonspherocytic hemolytic, due to G6PD deficiency | 2020-03-29 | criteria provided, single submitter | clinical testing | In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. This variant disrupts the p.Ala335 amino acid residue in G6PD. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 11499668, 16927025, 20602793, 21677401, 22293322, 25548459, 2606066). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0"). This variant has been observed in individual(s) with glucose-6-phosphate dehydrogenase deficiency (PMID: 5775246, 15625830, 7803800). This variant is not present in population databases (ExAC no frequency). This sequence change replaces alanine with aspartic acid at codon 335 of the G6PD protein (p.Ala335Asp). The alanine residue is moderately conserved and there is a moderate physicochemical difference between alanine and aspartic acid. |
Dunham Lab, |
RCV001379702 | SCV002599354 | pathogenic | Anemia, nonspherocytic hemolytic, due to G6PD deficiency | 2022-08-12 | criteria provided, single submitter | curation | Variant found in unrelated hemizygotes with deficiency, some with anemia (PS4_M, PP4). Decreased activity in red blood cells (11-19%) (PS3). Affects same amino acid as pathogenic 335A>T (ClinVar ID 10363) (PM5). Below expected carrier frequency in gnomAD (PM2). Post_P 0.997 (odds of pathogenicity 3158, Prior_P 0.1). |
Baylor Genetics | RCV003469642 | SCV004195401 | likely pathogenic | Malaria, susceptibility to | 2023-05-18 | criteria provided, single submitter | clinical testing | |
Juno Genomics, |
RCV004796619 | SCV005416074 | pathogenic | Malaria, susceptibility to; Anemia, nonspherocytic hemolytic, due to G6PD deficiency | criteria provided, single submitter | clinical testing | PM2_Supporting+PS4+PP4+PS3_Moderate+PM5 |